comparemela.com

Latest Breaking News On - Nedira salzman frenkel - Page 1 : comparemela.com

NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023

Investors interested in meeting the executive team and hearing NeuroSense s strategy, updates, and upcoming catalysts may register for the invitation-only event. CAMBRIDGE, Mass., July 17, 2023.

United statesUnited kingdomShiran zimriNedira salzman frenkelExchange commission onNeurosense therapeutics ltdPrnewswire neurosense therapeutics ltdVp business developmentSense therapeuticsAlon ben noonNeurosense therapeuticAnnual reportExchange commissionNeurosense therapeutics

NEUROSENSE THERAPEUTICS LTD TO PARTICIPATE IN RENMARK S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc. s live.

United kingdomNedira salzman frenkelRenmark financial communications incPrnewswire neurosense therapeutics ltdCompany investorBusiness developmentNeurosense therapeutics ltdSense therapeuticsRenmark financial communicationsVirtual non deal roadshow seriesAlon ben noonChief executive officerNeurosense and renmark financial communications inc

NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomLoma linda universityUnited statesSan franciscoNiva russekJeremy shefnerJeffrey rosenfeldCharles duncanFerenc tracikShiran zimriNedira salzman frenkelAmyotrophic lateral sclerosis consortiumNeurosense head of the scientific programCompany investigational new drugPrnewswire neurosense therapeutics ltdDrug administration

NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomNedira salzman frenkelNiva russek blumPrnewswire neurosense therapeutics ltdNeurosense vp business developmentNeurosense therapeutics ltdSense therapeuticsPartnering conference

EverythingALS and NeuroSense take aim at Lou Gehrig s disease

NeuroSense Therapeutics and EverythingALS partnership involves a patient-centric approach to drug development.

United statesNedira salzman frenkelPeter cohen foundationNeurosense therapeuticsIndu navarJohn hopkins

vimarsana © 2020. All Rights Reserved.